BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 28818705)

  • 21. Osteoporosis risk and management in BRCA1 and BRCA2 carriers who undergo risk-reducing salpingo-oophorectomy.
    Garcia C; Lyon L; Conell C; Littell RD; Powell CB
    Gynecol Oncol; 2015 Sep; 138(3):723-6. PubMed ID: 26086567
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preventing Ovarian Cancer through early Excision of Tubes and late Ovarian Removal (PROTECTOR): protocol for a prospective non-randomised multi-center trial.
    Gaba F; Robbani S; Singh N; McCluggage WG; Wilkinson N; Ganesan R; Bryson G; Rowlands G; Tyson C; Arora R; Saridogan E; Hanson H; Burnell M; Legood R; Evans DG; Menon U; Manchanda R;
    Int J Gynecol Cancer; 2021 Feb; 31(2):286-291. PubMed ID: 32907814
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Short-term impact of surgically induced menopause on cognitive function and wellbeing in women at high risk for ovarian cancer following risk-reducing bilateral salpingo-oophorectomy.
    Chang H; Kamara D; Bresee C; Lester J; Cass I
    Menopause; 2020 Dec; 28(4):354-359. PubMed ID: 33350669
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Severity and duration of menopausal symptoms after risk-reducing salpingo-oophorectomy.
    Stuursma A; van Driel CMG; Wessels NJ; de Bock GH; Mourits MJE
    Maturitas; 2018 May; 111():69-76. PubMed ID: 29673834
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk-reducing bilateral salpingo-oophorectomy and sexual health: a qualitative study.
    Brotto LA; Branco N; Dunkley C; McCullum M; McAlpine JN
    J Obstet Gynaecol Can; 2012 Feb; 34(2):172-178. PubMed ID: 22340066
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sexual functioning more than 15 years after premenopausal risk-reducing salpingo-oophorectomy.
    Terra L; Beekman MJ; Engelhardt EG; Heemskerk-Gerritsen BAM; van Beurden M; Roeters van Lennep JE; van Doorn HC; de Hullu JA; Van Dorst EBL; Mom CH; Slangen BFM; Gaarenstroom KN; van der Kolk LE; Collée JM; Wevers MR; Ausems MGEM; Van Engelen K; van de Beek I; Berger LPV; van Asperen CJ; Gomez Garcia EB; Maas AHEM; Hooning MJ; Aaronson NK; Mourits MJE; van Leeuwen FE
    Am J Obstet Gynecol; 2023 Apr; 228(4):440.e1-440.e20. PubMed ID: 36403862
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quality of life after risk-reducing surgery for breast and ovarian cancer prevention: a systematic review and meta-analysis.
    Wei X; Oxley S; Sideris M; Kalra A; Brentnall A; Sun L; Yang L; Legood R; Manchanda R
    Am J Obstet Gynecol; 2023 Oct; 229(4):388-409.e4. PubMed ID: 37059410
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early salpingectomy (TUbectomy) with delayed oophorectomy to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers (TUBA study): a prospective non-randomised multicentre study.
    Harmsen MG; Arts-de Jong M; Hoogerbrugge N; Maas AH; Prins JB; Bulten J; Teerenstra S; Adang EM; Piek JM; van Doorn HC; van Beurden M; Mourits MJ; Zweemer RP; Gaarenstroom KN; Slangen BF; Vos MC; van Lonkhuijzen LR; Massuger LF; Hermens RP; de Hullu JA
    BMC Cancer; 2015 Aug; 15():593. PubMed ID: 26286255
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk-reducing Salpingo-Oophorectomy in Women at Higher Risk of Ovarian and Breast Cancer: A Single Institution Prospective Series.
    Ricciardi E; Tomao F; Aletti G; Bazzurini L; Bocciolone L; Boveri S; Landoni F; Lapresa MT; Maruccio M; Parma G; Peccatori F; Petrella MC; Zanagnolo V; Colombo N; Maggioni A
    Anticancer Res; 2017 Sep; 37(9):5241-5248. PubMed ID: 28870960
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hormone Levels and Sexual Functioning After Risk-Reducing Salpingo-Oophorectomy.
    Johansen N; Liavaag AH; Mørkrid L; Michelsen TM
    Sex Med; 2018 Jun; 6(2):143-153. PubMed ID: 29631858
    [TBL] [Abstract][Full Text] [Related]  

  • 31. What happens after menopause? (WHAM): A prospective controlled study of symptom profiles up to 12 months after pre-menopausal risk-reducing salpingo-oophorectomy.
    Moss KM; Mishra GD; Krejany EO; Hickey M
    Gynecol Oncol; 2022 Oct; 167(1):58-64. PubMed ID: 35933227
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Factors influencing uptake and timing of risk reducing salpingo-oophorectomy in women at risk of familial ovarian cancer: a competing risk time to event analysis.
    Manchanda R; Burnell M; Abdelraheim A; Johnson M; Sharma A; Benjamin E; Brunell C; Saridogan E; Gessler S; Oram D; Side L; Rosenthal AN; Jacobs I; Menon U
    BJOG; 2012 Apr; 119(5):527-36. PubMed ID: 22260402
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A prospective study of quality of life among women undergoing risk-reducing salpingo-oophorectomy versus gynecologic screening for ovarian cancer.
    Fang CY; Cherry C; Devarajan K; Li T; Malick J; Daly MB
    Gynecol Oncol; 2009 Mar; 112(3):594-600. PubMed ID: 19141360
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bone mineral density and fractures after risk-reducing salpingo-oophorectomy in women at increased risk for breast and ovarian cancer.
    Fakkert IE; Abma EM; Westrik IG; Lefrandt JD; Wolffenbuttel BH; Oosterwijk JC; Slart RH; van der Veer E; de Bock GH; Mourits MJ
    Eur J Cancer; 2015 Feb; 51(3):400-8. PubMed ID: 25532426
    [TBL] [Abstract][Full Text] [Related]  

  • 35. What happens after menopause? (WHAM): A prospective controlled study of vasomotor symptoms and menopause-related quality of life 12 months after premenopausal risk-reducing salpingo-oophorectomy.
    Hickey M; Moss KM; Krejany EO; Wrede CD; Brand A; Kirk J; Symecko HL; Domchek SM; Tejada-Berges T; Trainer A; Mishra GD
    Gynecol Oncol; 2021 Oct; 163(1):148-154. PubMed ID: 34312002
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Climacteric symptoms in women undergoing risk-reducing bilateral salpingo-oophorectomy.
    Benshushan A; Rojansky N; Chaviv M; Arbel-Alon S; Benmeir A; Imbar T; Brzezinski A
    Climacteric; 2009 Oct; 12(5):404-9. PubMed ID: 19479488
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Psychological and sexual aspects of the menopause and HRT.
    Pearce MJ; Hawton K
    Baillieres Clin Obstet Gynaecol; 1996 Sep; 10(3):385-99. PubMed ID: 8931901
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prospective follow-up of quality of life for participants undergoing risk-reducing salpingo-oophorectomy or ovarian cancer screening in GOG-0199: An NRG Oncology/GOG study.
    Mai PL; Huang HQ; Wenzel LB; Han PK; Moser RP; Rodriguez GC; Boggess J; Rutherford TJ; Cohn DE; Kauff ND; Phillips KA; Wilkinson K; Wenham RM; Hamilton C; Powell MA; Walker JL; Greene MH; Hensley ML
    Gynecol Oncol; 2020 Jan; 156(1):131-139. PubMed ID: 31759774
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of risk-reducing gynaecological surgery in premenopausal women at high risk of endometrial and ovarian cancer due to Lynch syndrome.
    Moldovan R; Keating S; Clancy T
    Fam Cancer; 2015 Mar; 14(1):51-60. PubMed ID: 25342222
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Addressing sexual dysfunction after risk-reducing salpingo-oophorectomy: effects of a brief, psychosexual intervention.
    Bober SL; Recklitis CJ; Bakan J; Garber JE; Patenaude AF
    J Sex Med; 2015 Jan; 12(1):189-97. PubMed ID: 25311333
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.